How do pediatric familial hypercholesterolemia clinic nurses explain to Spanish-speaking families why statin must continue when LDL has improved significantly from the untreated baseline?

The LDL-improved-so-we-can-stop conversation is one of the most common in the pediatric FH clinic and requires the nurse to reframe the family's success narrative without dismissing the real progress that has been made. The family is right that LDL 178 is better than LDL 285 — that improvement is real and is the result of the medication working correctly. The reframe needed is that in familial hypercholesterolemia, the goal of treatment is not improvement from the untreated baseline but achievement and maintenance of a specific LDL target over a lifetime. The NHLBI and AHA pediatric lipid guidelines establish an LDL treatment target of less than 130 mg/dL for children with heterozygous FH, and less than 100 mg/dL as an optimal goal, because the cardiovascular risk in FH is proportional to lifetime cumulative LDL exposure — the product of LDL concentration times years of exposure, sometimes called LDL-years. LDL 178 mg/dL in an 11-year-old with HeFH represents approximately 70 percent of the lifetime cardiovascular risk reduction the family needs; the remaining 30 percent requires further dose optimization or combination therapy to bring LDL to target. Why does stopping return LDL to 285? Because the LDLR mutation that causes FH is permanent and cannot be cured by a medication — atorvastatin works by inhibiting HMG-CoA reductase in the liver, which reduces endogenous cholesterol synthesis and triggers hepatocytes to upregulate expression of functional LDL receptors from the remaining intact LDLR allele (in heterozygous FH, one allele is broken and one is functional). As long as atorvastatin continues to inhibit intracellular cholesterol synthesis, the hepatocyte responds by increasing LDLR expression and clearing more LDL from the circulation. When atorvastatin is stopped, intracellular cholesterol synthesis resumes, the upregulation signal disappears, LDLR expression returns to baseline, and LDL returns to the pre-treatment concentration within two to four weeks. The broken allele is unchanged by any of this — it was broken before atorvastatin, it is broken during atorvastatin, and it is still broken after atorvastatin stops. The Spanish frame: 'El LDL bajó de 285 a 178 — eso es exactamente lo que queremos que haga la atorvastatina, y eso es una mejora real. El problema es que 178 no es nuestro objetivo — nuestro objetivo es menos de 130, y idealmente menos de 100. La mutación en el gen de Carlos sigue ahí. No la curó la atorvastatina — lo que hace la atorvastatina es decirle al hígado que exprese más receptores para recoger el LDL del torrente sanguíneo. Mientras la atorvastatina está presente, el hígado responde. Cuando la paramos, el hígado deja de responder, y en dos a cuatro semanas el LDL vuelve a 285. La mutación nunca cambió — solo cambia la señal que le damos al hígado para que trabaje más.'

How do pediatric familial hypercholesterolemia clinic nurses explain to Spanish-speaking grandmothers why a 9-year-old needs a cholesterol medication?

The 'cholesterol is an old person's disease' conversation requires the nurse to distinguish between two entirely different causes of elevated cholesterol: acquired hypercholesterolemia driven by diet, obesity, insulin resistance, and aging (which is indeed more common in older adults and is influenced by lifestyle), and familial hypercholesterolemia, which is caused by a heritable mutation in the LDLR gene that produces a broken LDL receptor from conception and is completely independent of diet. The grandmother's belief is accurate for the common form of high cholesterol that affects most adults — that form is indeed lifestyle-related and more prevalent with age. FH is different in two critical ways: its cause is genetic not dietary, and its timeline for cardiovascular harm is measured in decades starting from childhood. Sofía's LDL receptor — specifically the LDLR gene variant she inherited from her mother — produces a protein that cannot properly bind and internalize LDL particles at the hepatocyte surface. In a healthy person, LDL receptors on liver cells bind the apolipoprotein B-100 on LDL particles, pull them into the cell by endocytosis, degrade the LDL, and recycle the receptor back to the surface — this process clears approximately 70 percent of circulating LDL. In Sofía's hepatocytes, the mutant receptor is either misfolded, reduced in number, or defective in binding — depending on the specific LDLR variant — so LDL clearance is impaired at approximately 50 percent of normal efficiency for a heterozygous patient. The result is persistent LDL elevation that is present at birth, measurable in cord blood in FH infants, and completely unaffected by the composition of meals. Sofía can eat the most perfect Mediterranean diet available and her LDL will remain elevated because the liver cannot clear it fast enough regardless of how little arrives from dietary fat. Dietary modification reduced Sofía's LDL from 256 to 243 — a 5 percent reduction — which demonstrates this point: diet modestly affects the input side of the LDL equation but not the clearance-side defect that is the actual cause of the problem. Why does a 9-year-old need treatment? Because Sofía's mother Carmen had a myocardial infarction at age 32 after FH was undiagnosed until 28 — meaning her arteries accumulated 28 years of LDL 295 silently before treatment began. The AHA and AAP recommend statin initiation in HeFH children at age 8 to 10 specifically to interrupt this process early, before arterial cholesterol deposition reaches the threshold for plaque rupture and acute coronary syndromes. The Spanish frame: 'Entiendo completamente que parece extraño darle un medicamento para el colesterol a una niña de 9 años. La razón por la que tiene sentido es que el colesterol de Sofía no es el mismo tipo de colesterol que vemos en adultos que comen mucha grasa o tienen sobrepeso. El colesterol de Sofía viene de un gen — el gen de su mamá, que pasó a Sofía. Ese gen produce un receptor en el hígado que no puede recoger el LDL bien. No importa lo que Sofía coma — el hígado de Sofía no puede limpiar el LDL como debería. Estamos tratando de que no le pase lo mismo que a su mamá, que tuvo un infarto a los 32 años porque nadie supo que tenía este gen hasta que ya había daño. Si empezamos ahora, tenemos una oportunidad real de que Sofía llegue a los 40, 50, 60 años con arterias sanas.'

How do pediatric familial hypercholesterolemia clinic nurses explain that statins are safe for growing children and adolescents?

The statin-and-growth conversation requires the nurse to address two distinct concerns that online sources often conflate: the concern about growth plates and linear height, and the concern about muscle toxicity. Both concerns are real in the general sense that statins have been studied for musculoskeletal effects and that growth plate safety is an appropriate question to ask before prescribing any chronic medication to a growing child. The evidence on both points is reassuring. On growth and bone: the landmark Wiegman et al. 2004 New England Journal of Medicine randomized controlled trial enrolled 214 children ages 8 to 18 with heterozygous FMF and randomized them to pravastatin or placebo for two years. At study end, there were no significant differences between groups in height, weight, body mass index, bone mineral density measured by DEXA, or Tanner pubertal staging. Subsequent studies with atorvastatin, rosuvastatin, and simvastatin in children have replicated these findings. The mechanistic reason that statins do not affect growth plates is that longitudinal bone growth in the physis (growth plate) depends on chondrocyte proliferation in the proliferative zone, chondrocyte hypertrophy in the hypertrophic zone, and matrix calcification — processes that are driven primarily by growth hormone, insulin-like growth factor 1, parathyroid hormone-related protein, and Indian hedgehog signaling. HMG-CoA reductase inhibition reduces intracellular cholesterol synthesis and downstream mevalonate pathway products (such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate used for protein prenylation), but the concentrations of statin reaching the growth plate in pediatric therapeutic doses are insufficient to significantly impair the chondrocyte function that drives growth. On muscle: statin-associated myopathy — ranging from asymptomatic CK elevation to clinical myalgia to rare rhabdomyolysis — is a real adverse effect that is dose-dependent, more common in adults with polypharmacy (especially statins combined with fibrates, cyclosporine, or macrolide antibiotics), and more common at higher doses. In children on pediatric doses (pravastatin 20-40 mg, atorvastatin 10-20 mg, rosuvastatin 5-10 mg), CK elevation above 10 times the upper limit of normal is very rare. Pediatric FH statin guidelines recommend baseline CK measurement and periodic monitoring; any child with unexplained muscle pain should have CK checked. The Spanish frame: 'Entiendo la preocupación — usted leyó algo sobre los músculos y el crecimiento, y eso es exactamente el tipo de pregunta que uno debería hacer antes de dar un medicamento a un adolescente que está creciendo. Lo que sabemos de los estudios es que los estatinas a la dosis que le damos a Andrés no afectan las placas de crecimiento. Hay un estudio grande — 214 niños con FH, la misma enfermedad de Andrés — donde midieron la altura, el peso, la densidad de los huesos, y el desarrollo de pubertad cada seis meses durante dos años. Los niños que tomaron el medicamento crecieron igual que los que tomaron el placebo. Las placas de crecimiento no dependen del camino que bloquean las estatinas — dependen de la hormona del crecimiento y el factor IGF-1, que no se afectan. Y los músculos: el riesgo de músculo existe en adultos con dosis altas y múltiples medicamentos. A Andrés le revisamos el CK en cada visita — ha estado normal cada vez. Lo que sí afecta los vasos sanguíneos de Andrés es el LDL a 298. Ese no espera a que termine de crecer.'

How do pediatric familial hypercholesterolemia clinic nurses explain the long-term cardiovascular risk of untreated FH to Spanish-speaking families in concrete terms?

The long-term risk conversation is the foundational communication in the pediatric FH clinic, and the challenge is that the harm being prevented is invisible, painless, and 20 to 40 years in the future — which makes it extremely difficult for families to weigh against the daily burden of giving a child a medication for a condition that produces no current symptoms. The most concrete and evidence-based way to frame the risk is in terms of LDL-years — the cumulative exposure to elevated LDL over a lifetime — and the family history, which in most FH families includes at least one first- or second-degree relative with premature cardiovascular disease. Untreated heterozygous FH produces average LDL concentrations of 200 to 400 mg/dL throughout life. Population studies of untreated HeFH patients, including the Dutch nationwide FH registry, show that without treatment, 50 percent of men with HeFH have a myocardial infarction before age 50, and 30 percent of women before age 60. With statin treatment from adulthood, this risk is reduced by approximately 40 to 60 percent. The critical contribution of pediatric treatment is that atherosclerotic plaque formation in FH begins in childhood — coronary intima-media thickness measurements in children with HeFH show that the coronary arteries are already thicker than in children without FH at ages 8 to 12, and that this difference correlates with LDL-years accumulated from birth, not from adulthood. Every year of LDL 285 in a child with FH represents a year of cholesterol depositing in the coronary endothelium silently, without pain, without symptoms, and without clinical events — until the plaque becomes large enough to rupture. Starting a statin at age 8 to 11 instead of age 28 to 35 (when most adult FH diagnoses occur after a first event) buys 20 to 25 years of lower LDL before the typical age of first cardiovascular events in untreated FH. The Dutch FH cascade screening data show that children started on statins before age 18 have substantially lower coronary event rates than those started in adulthood, even when adult LDL concentrations are similar. The Spanish frame: 'La razón por la que el FMF se trata desde la infancia no es porque Carlos tiene síntomas ahora — es porque el colesterol LDL a 285 está depositándose en las arterias del corazón de Carlos ahora, hoy, sin que él sienta nada. Las arterias del corazón no tienen receptores de dolor — el daño es silencioso durante 20, 30 años. Cuando un hombre con FH no tratado tiene un infarto a los 44 años — como el papá de Carlos — eso no es una coincidencia ni mala suerte. Son 44 años de LDL alto acumulándose. Si reducimos el LDL de Carlos ahora a menos de 130 y lo mantenemos ahí, su riesgo de tener ese infarto a los 44 es dramáticamente menor — probablemente no lo va a tener a los 44. Eso es lo que estamos haciendo: no tratando algo que lo molesta hoy. Estamos protegiendo el corazón de Carlos para cuando tenga 40, 50 años.'

What are the key Spanish phrases pediatric familial hypercholesterolemia clinic nurses use when explaining LDL receptor function, FH genetics, and statin continuation to Spanish-speaking families?

Pediatric familial hypercholesterolemia clinic nurses working with Spanish-speaking families need clinical Spanish for five recurring communication moments: explaining why LDL improved but is not yet at target; explaining the permanent nature of LDLR mutations; explaining why FH is not a diet disease; explaining statin safety in growing children; and explaining the long-term cardiovascular stakes. For LDL target versus LDL improvement: 'El LDL bajó y eso es exactamente lo que queríamos. Pero en el FH, nuestra meta no es que baje un poco — nuestra meta es menos de 130. A 178 todavía estamos el doble de donde necesitamos estar. Si paramos ahora, en tres semanas el LDL vuelve a 285, porque la mutación en el gen de Carlos nunca cambió — lo que hace la atorvastatina es decirle al hígado que trabaje más con los receptores que sí funcionan.' For LDLR mutation permanence: 'La mutación LDLR que tiene Carlos está en cada célula de su cuerpo y va a estar ahí para toda su vida. No es una infección que se cura. La atorvastatina no repara el gen — lo que hace es estimular al hígado para que use más agresivamente los receptores buenos que sí tiene. Cuando paramos la atorvastatina, esa estimulación desaparece, el hígado vuelve a su ritmo normal, y el LDL sube de vuelta.' For FH versus diet-related cholesterol: 'El colesterol de Sofía no viene de lo que come — viene de su gen. Los receptores en el hígado de Sofía no pueden recoger el LDL bien. Probamos seis meses de dieta: el LDL bajó de 256 a 243 — solo un 5 por ciento. Eso nos dice que la dieta ayuda un poco pero no es suficiente, porque el problema no está en cuánto LDL entra sino en que el hígado no puede sacarlo.' For statin safety in children: 'Los estudios muestran que las estatinas a esta dosis no afectan el crecimiento ni los huesos. Las placas de crecimiento usan un mecanismo diferente — hormona del crecimiento e IGF-1 — que las estatinas no tocan. El riesgo de músculo existe en adultos con dosis altas; en niños con la dosis de Sofía, el riesgo es muy bajo y lo monitoreamos con el CK en cada visita.' For cardiovascular stakes: 'Cada año que el LDL de Andrés está a 298, esa cantidad de colesterol se está depositando en las arterias del corazón silenciosamente. Sin que le duela. Sin que lo sienta. El daño no espera a que termine de crecer. Si esperamos a los 18, son cuatro años más de LDL 298 — cuatro años que en el FH no tratado se convierten en placas en las arterias coronarias que no pueden revertirse.'

Spanish for pediatric familial hypercholesterolemia clinic nurses — the father who cannot understand why atorvastatin must continue when his son’s LDL went from 285 to 178 not knowing LDL 178 is still double the FH target; the grandmother who cannot understand why a 9-year-old needs a cholesterol medication not knowing FH is an LDLR mutation that impairs hepatic LDL clearance permanently from birth regardless of diet; and the mother who wants to stop because she read statins affect muscle growth not knowing statins have no effect on growth plates

The pediatric familial hypercholesterolemia clinic nurse’s communication challenge

The pediatric familial hypercholesterolemia clinic nurse works in a specialty defined by a temporal paradox: the cardiovascular harm being prevented is silent, painless, and two to three decades in the future, while the treatment — a daily medication in a child who feels completely well — is visible, present, and demands an explanation every visit. When the treatment produces measurable improvement in the number the family has learned to watch, stopping the treatment feels like the rational next step. When the child eating the Mediterranean diet their grandmother has cooked all her life somehow still has elevated cholesterol, a hereditary explanation conflicts with deeply held beliefs about how cholesterol works. When the child entering puberty and growing at the fastest rate of their life is taking a medication the family has read can affect muscles and bones, the timing of the concern is not coincidental.

Three recurrent misalignments define the communication challenge in the pediatric FH clinic with particular urgency for nurses working with Spanish-speaking families.

The first is the statin discontinuation after measurable LDL improvement. An 11-year-old with confirmed heterozygous FH has been on atorvastatin for eight months. His LDL has fallen from 285 to 178 milligrams per deciliter — a 38 percent reduction. His father, an electrician who has watched every number on every lab result for a year, concludes that the treatment has worked and the medication is no longer needed. The nurse must explain that in FH, “worked” means something different from what it means in a course of antibiotics: LDL 178 is not at the pediatric FH treatment target of less than 130 mg/dL; the LDLR mutation that caused LDL 285 is present in every cell of his body and is unchanged by atorvastatin; stopping the medication removes the hepatic signal that drove LDL down and returns LDL to 285 within weeks; and the father’s own father had a myocardial infarction at age 44 — the cardiovascular trajectory Carlos is on without continuous treatment from childhood.

The second is the family belief that cholesterol is an adult disease unrelated to a healthy child’s diet. A 9-year-old’s grandmother has taken over her daily medications while the mother recovers from a cardiac procedure. She gives the rosuvastatin dutifully but is deeply uncomfortable with it and wants to discuss stopping. The nurse must explain that familial hypercholesterolemia is an autosomal dominant genetic condition present from birth — not an acquired metabolic disease of aging — and that the dietary approach the grandmother trusts (eating well, avoiding fats, home-cooked meals every day) demonstrably reduced Sofía’s LDL by only 5 percent over six months because the problem is in hepatic clearance, not dietary intake. The grandmother’s dietary instincts are correct for the common acquired hypercholesterolemia that affects most older adults. They are insufficient for a broken LDL receptor. And Sofía’s mother Carmen had a myocardial infarction at age 32 from exactly the untreated FH trajectory Sofía is on.

The third is the concern about statin safety during active growth. A 14-year-old in a growth spurt — eight centimeters in the past year — has been on atorvastatin for 18 months. His mother has read online that statins can affect muscles and bone development and wants to pause the medication until he finishes growing. The nurse must explain that multiple randomized controlled trials, including the landmark 2004 New England Journal of Medicine study in 214 children ages 8 to 18 with HeFH, found no difference in height velocity, bone mineral density, Tanner staging, or growth plate appearance between statin and placebo over two years — and that the mechanistic reason is that chondrocyte growth plate function depends on growth hormone and IGF-1 signaling, not the mevalonate pathway that statins inhibit. The muscle concern is real and monitored, but stopping atorvastatin during a growth spurt does not protect anything related to growth; it simply allows LDL 298 to continue depositing cholesterol in coronary arteries during those growing months.

Three conversations from the pediatric familial hypercholesterolemia clinic:

Scenario 1: Carlos Jiménez-Robles — 11 years old, Houston, Texas

Carlos Jiménez-Robles had received his diagnosis of familial hypercholesterolemia the way most children do — through cascade screening after a parent’s cardiovascular event. His father Manuel Jiménez-Torres, an electrician, had been referred to a cardiologist at age 43 after a routine occupational health exam showed a total cholesterol of 334 mg/dL. The cardiologist had ordered a coronary CT angiogram. The result had been alarming: diffuse calcification in the left anterior descending artery, a 60 percent stenosis in the proximal LAD that the cardiologist described as significant enough to warrant a stress test immediately. Manuel had undergone a percutaneous coronary intervention at age 44 — a stent in the LAD — six months before Carlos was brought to the pediatric lipid clinic.

The genetic workup on Manuel had confirmed LDLR pathogenic variant c.1586G>A (p.Gly529Glu) — a missense mutation in exon 11 of the LDL receptor gene that produces a receptor with severely reduced binding affinity for apolipoprotein B-100. The cardiologist had recommended cascade screening of all first-degree relatives. Manuel’s older sister had been screened and found to have LDL 278 mg/dL and the same variant. Carlos had been screened at age 10: fasting LDL 268 mg/dL on the first draw, 285 mg/dL on the confirmatory second draw three weeks later. The pediatric lipid clinic had confirmed HeFH: LDL above the 95th percentile for age, confirmed LDLR pathogenic variant, first-degree relative with documented premature cardiovascular disease (father’s LAD stent at age 44).

The first six months had been a dietary trial — standard pediatric FH protocol. The family had worked with the clinic dietitian: the National Cholesterol Education Program Step II diet, reduction in saturated fat to less than 7 percent of calories, dietary cholesterol below 200 mg per day, addition of plant stanol ester margarine at the main meal. Carlos’s mother Elena had been meticulous: she had pulled every label, replaced the lard in the traditional cooking with olive oil, made the tamales without manteca for the holidays. At the six-month recheck, the LDL was 264 mg/dL. A 7.4 percent reduction. Insufficient.

Atorvastatin 10 mg daily had been started at that visit. Eight months later, Carlos arrived at his first statin follow-up. Fasting LDL: 178 mg/dL. Manuel was with him, and he arrived with the lab printout from the pharmacy portal folded in his shirt pocket.

“Mire — de 285 a 178,” he said, placing the paper on the exam table before the nurse, Elena Morales-Cisneros, had finished reviewing the chart. “Eso es mucho. Bajó casi cien puntos. Carlos no tiene ningún síntoma, come bien, su mamá cambió toda la comida de la casa. Yo creo que ya hizo su trabajo la medicina. ¿No podemos ver si puede seguir sin ella?” (Look — from 285 to 178. That is a lot. It dropped almost a hundred points. Carlos has no symptoms, he eats well, his mother changed all the food in the house. I think the medication already did its job. Can we not see if he can continue without it?)

Carlos was on the exam table, looking at his sneakers.

Nurse Elena sat across from Manuel and took the lab printout. She did not look at it — she had already seen the number in the chart. She looked at Manuel instead. “Señor Jiménez, lo que usted está viendo en ese papel es real. El LDL bajó de 285 a 178. Eso es exactamente lo que la atorvastatina hace cuando funciona correctamente, y eso es buena noticia. Voy a explicarle por qué a pesar de eso no podemos pararla, y voy a empezar por dónde queremos llegar.” (Mr. Jiménez, what you are seeing on that paper is real. The LDL went from 285 to 178. That is exactly what atorvastatin does when it works correctly, and that is good news. I am going to explain to you why despite that we cannot stop it, and I am going to start with where we want to get to.)

Manuel leaned back slightly.

“El objetivo para Carlos no es que el LDL baje de 285. El objetivo es que el LDL llegue a menos de 130 — idealmente menos de 100. Eso es lo que marcan las guías para niños con FH porque el riesgo cardiovascular del FH depende de cuánto tiempo el LDL estuvo alto multiplicado por cuán alto estuvo — no de un número en un día. A 178, Carlos tiene el doble del LDL que queremos. Todavía estamos a mitad de camino.” (The goal for Carlos is not that the LDL goes down from 285. The goal is that the LDL reaches less than 130 — ideally less than 100. That is what the guidelines say for children with FH because the cardiovascular risk of FH depends on how long the LDL was high multiplied by how high it was — not a number on one day. At 178, Carlos has double the LDL we want. We are still halfway there.)

Manuel frowned. “¿Y si paramos un tiempo y vemos?” (And if we stop for a while and see?)

“Si paramos, en dos a cuatro semanas el LDL vuelve a 285. No a 200, no a 230 — a 285. La razón es que la mutación que tiene Carlos nunca cambió. La atorvastatina no curó el gen — eso no es posible. Lo que hace la atorvastatina es bloquear la producción de colesterol en el hígado, y cuando el hígado detecta que tiene menos colesterol interno, responde activando más los receptores de LDL que sí funcionan — Carlos tiene un gen bueno y un gen con la mutación; la atorvastatina hace que el gen bueno trabaje más. Cuando paramos la atorvastatina, esa señal desaparece, el gen bueno vuelve a su nivel base, y el LDL sube de vuelta en semanas.” (If we stop, in two to four weeks the LDL returns to 285. Not to 200, not to 230 — to 285. The reason is that the mutation Carlos has never changed. Atorvastatin did not cure the gene — that is not possible. What atorvastatin does is block cholesterol production in the liver, and when the liver detects it has less internal cholesterol, it responds by activating the LDL receptors that do work more aggressively — Carlos has one good gene and one gene with the mutation; atorvastatin makes the good gene work harder. When we stop atorvastatin, that signal disappears, the good gene returns to its baseline level, and the LDL goes back up within weeks.)

Carlos looked up. “¿El gen malo está ahí para siempre?” (Is the bad gene there forever?)

“Sí. Igual que el papá de tu papá — él también tenía ese gen. Por eso se lo pasó a tu papá y a tu tía, y tu papá te lo pasó a ti. No desaparece, no cambia, no se cura. Lo que podemos hacer es controlar lo que produce — el LDL alto.” (Yes. The same as your father’s father — he also had that gene. That is why he passed it to your father and your aunt, and your father passed it to you. It does not disappear, it does not change, it is not cured. What we can do is control what it produces — the high LDL.)

Manuel was quiet. He looked at the folded lab printout. “¿Y si llega a 130, podemos pensar en parar?” (And if it reaches 130, can we think about stopping?)

“No — 130 es el objetivo de mantenimiento, no la meta de llegada. Para el FH, la meta es mantener el LDL por debajo de 130 de forma continua — para toda la vida de Carlos. La razón no es burocrática. Es que cada año que el LDL estuvo a 285, esa cantidad de colesterol se fue depositando en las arterias del cora&zón de Carlos silenciosamente — sin que Carlos sienta nada, sin ningún síntoma. Las arterias del corazón no tienen receptores de dolor. El daño es invisible durante décadas. Su papá de usted tuvo el infarto a los 44 — eso no fue mala suerte. Fueron 44 años de LDL alto acumulándose. Carlos tiene 11 años. Si mantenemos el LDL de Carlos por debajo de 130 desde ahora, cuando Carlos tenga 44 el cora&zón va a estar en un lugar completamente diferente al que estarían las arterias de su padre sin tratamiento.” (No — 130 is the maintenance target, not the finish line. For FH, the goal is to keep LDL below 130 continuously — for Carlos’s entire life. The reason is not bureaucratic. It is that every year the LDL was at 285, that amount of cholesterol was depositing in Carlos’s heart arteries silently — without Carlos feeling anything, without any symptoms. The heart arteries have no pain receptors. The damage is invisible for decades. Your father had the heart attack at 44 — that was not bad luck. It was 44 years of high LDL accumulating. Carlos is 11 years old. If we keep Carlos’s LDL below 130 from now on, when Carlos is 44 his heart will be in a completely different place than his father’s arteries would have been without treatment.)

Manuel was still for a long moment. He looked at his son — Carlos, who had started stacking the tissue box on top of the blood pressure cuff display to see if it would balance. Then back at the nurse. “¿Y lo de 178 es un buen comienzo?” (And the 178 is a good start?)

“Es un muy buen comienzo. Bajamos 107 puntos en ocho meses. Vamos a hacer dos cosas: subir la dosis de atorvastatina a 20 miligramos para ver si llegamos a 130, y hablar con el médico sobre si Carlos es candidato para añadir ezetimibe — es otro medicamento que bloquea la absorción de colesterol en el intestino y funciona por un mecanismo diferente; juntos pueden llegar donde atorvastatina sola no llega. El objetivo es llegar a menos de 130 y quedarnos ahí.” (It is a very good start. We came down 107 points in eight months. We are going to do two things: increase the atorvastatin dose to 20 milligrams to see if we can reach 130, and talk with the doctor about whether Carlos is a candidate to add ezetimibe — it is another medication that blocks cholesterol absorption in the intestine and works by a different mechanism; together they can reach where atorvastatin alone cannot. The goal is to get below 130 and stay there.)

Manuel refolded the lab printout carefully and put it back in his pocket. “Está bien,” he said. “Pero si llegamos a 100, volvemos a hablar.” (All right. But if we reach 100, we talk again.)

“Cuando lleguemos a 100, lo primero que hacemos es decírselo.” (When we reach 100, the first thing we do is tell you.)

Scenario 2: Sofía Mendoza-García — 9 years old, San Antonio, Texas

Sofía Mendoza-García had been enrolled in the pediatric FH cascade screening clinic when she was eight years old, three weeks after her mother Carmen Mendoza-Reyes had been discharged from the coronary care unit following a non-ST-elevation myocardial infarction at age 32. Carmen had been cooking breakfast for her two daughters when the chest pressure started. By the time the ambulance arrived, she was diaphoretic and in pain radiating to her jaw. The troponin at the ED had been 3.4 micrograms per liter. Cardiac catheterization had found diffuse coronary artery disease with a 75 percent stenosis in the right coronary artery and a 45 percent stenosis in the circumflex — the atherosclerosis of a 60-year-old, in a 32-year-old who ran five kilometers three times a week and did not smoke.

Carmen had been diagnosed with heterozygous FH at age 28, when a routine cholesterol panel had returned LDL 295 mg/dL. She had been started on rosuvastatin, the LDL had fallen to 178 mg/dL, and her cardiologist had expressed cautious optimism. But 28 years of LDL 295 — from birth to diagnosis — had already been depositing cholesterol in her coronary endothelium. The statin had stopped the accumulation. It had not reversed what had already formed.

Sofía’s screening had confirmed LDLR mutation identical to her mother’s. LDL 256 mg/dL at age eight. After six months of dietary modification — meticulous: Carmen had the dietitian at the pediatric clinic on her phone’s contact list and sent photos of every new food she bought — Sofía’s LDL had come down to 243 mg/dL. A 5.1 percent reduction. Rosuvastatin 5 mg daily had been started. At the nine-month follow-up with the current nurse visit, LDL was 148 mg/dL.

But Carmen had been hospitalized again — this time for an elective cardiac rehabilitation procedure — and Sofía had been living with her maternal grandmother, Abuela Dolores Mendoza-Vega, for six weeks. Abuela Dolores was 68, a retired school lunch supervisor, and she had been giving Sofía the rosuvastatin every morning as Carmen had instructed. But she had also been thinking about it, and she had thoughts.

“Mire, yo no quiero ser irrespetuosa,” she said, settling into the chair across from pediatric FH clinic nurse Patricia Herrera-Fuentes, with Sofía sitting beside her braiding her own ponytail. “Yo le doy la pastilla todos los días como me dijo Carmen. Pero no entiendo por qué una niña de 9 años necesita medicina para el colesterol. Eso es una enfermedad de viejos. Yo tengo 68 años y nunca en mi vida he tomado medicina para el colesterol. Sofía come bien — yo cocino todos los días, no les doy comida de paquete, nada de McDonald’s. ¿No puede simplemente comer bien y ya? ¿Por qué tiene que tomar pastillas una niña que está perfectamente sana?” (Look, I do not want to be disrespectful. I give her the pill every day as Carmen told me. But I do not understand why a 9-year-old girl needs medication for cholesterol. That is an old person’s disease. I am 68 years old and never in my life have I taken cholesterol medication. Sofía eats well — I cook every day, I do not give her packaged food, no McDonald’s. Can she not simply eat well and that is enough? Why does she have to take pills, a girl who is perfectly healthy?)

Patricia sat across from Abuela Dolores and thought for a moment about where to begin. “Abuela Dolores, gracias por darle la pastilla todos los días y por traerla hoy. Quiero responder a su pregunta lo mejor que pueda porque usted tiene toda la razón en muchas cosas. El colesterol sí es más común en personas mayores. Y comer bien sí ayuda. El problema es que el colesterol de Sofía no viene de lo que come — viene de un gen.” (Abuela Dolores, thank you for giving her the pill every day and for bringing her today. I want to answer your question as well as I can because you are completely right about many things. Cholesterol is indeed more common in older people. And eating well does help. The problem is that Sofía’s cholesterol does not come from what she eats — it comes from a gene.)

Abuela Dolores folded her hands. “Explíqueme.” (Explain it to me.)

“En la mayoría de las personas, el colesterol alto viene de la dieta, del peso, de la edad, de no hacer ejercicio — eso es lo que usted conoce, y eso sí se controla con la comida. El colesterol de Sofía es diferente. Sofía tiene una mutación en el gen LDLR. Ese gen produce los receptores en el hígado que recogen el LDL de la sangre — el colesterol malo — y lo meten dentro del hígado para procesarlo. En una persona sin la mutación, esos receptores funcionan bien y el hígado limpia el LDL de la sangre continuamente. En Sofía, un copy del gen está dañado. Los receptores que ese gen produce no funcionan bien. El resultado es que el hígado de Sofía solo puede limpiar la mitad del LDL que debería. El LDL se acumula en la sangre. Y eso pasa desde que Sofía nació.” (In most people, high cholesterol comes from diet, from weight, from age, from not exercising — that is what you know, and that is controlled with food. Sofía’s cholesterol is different. Sofía has a mutation in the LDLR gene. That gene produces the receptors in the liver that collect LDL from the blood — the bad cholesterol — and take it inside the liver to process it. In a person without the mutation, those receptors work well and the liver continuously cleans LDL from the blood. In Sofía, one copy of the gene is damaged. The receptors that gene produces do not work well. The result is that Sofía’s liver can only clean half of the LDL it should. The LDL accumulates in the blood. And this has been happening since Sofía was born.)

Abuela Dolores was quiet. Sofía had stopped braiding. “¿Y la comida no lo arregla?” (And the food does not fix it?)

“La dieta ayuda un poco. Probamos seis meses: Carmen cambió absolutamente toda la comida de la casa, trabajó con la nutricionista, quitó las grasas saturadas, todo. El LDL de Sofía bajó de 256 a 243 — solo un 5 por ciento. Eso nos dice que la dieta ayuda con la parte que viene de lo que uno come, pero el problema principal de Sofía no está en cuánto colesterol entra en la comida — está en que el hígado no puede sacarlo. Eso la dieta no lo puede corregir. Para eso necesitamos la rosuvastatina, que le da al hígado una señal para activar más los receptores que sí funcionan.” (Diet helps a little. We tried six months: Carmen absolutely changed all the food in the house, worked with the nutritionist, removed saturated fats, everything. Sofía’s LDL went from 256 to 243 — only 5 percent. That tells us that diet helps with the part that comes from what one eats, but Sofía’s main problem is not how much cholesterol comes in through food — it is that the liver cannot take it out. Diet cannot fix that. For that we need rosuvastatin, which gives the liver a signal to activate the receptors that do work more aggressively.)

Abuela Dolores looked at Sofía for a moment. “¿Y Carmen tuvo el infarto por eso?” (And Carmen had the heart attack because of that?)

“Sí. Carmen tiene la misma mutación que Sofía. Nadie lo sabía hasta que Carmen tenía 28 años. Esos 28 años de LDL alto — desde que nació — se fueron acumulando en las arterias del cora&zón de Carmen silenciosamente, sin síntomas. Las arterias del corazón no duelen cuando se estreñan — el daño es invisible. Cuando Carmen llegó a los 32 años, ya había suficiente placa acumulada para causar el infarto. Empezó el tratamiento a los 28, pero había demasiado daño ya hecho.” (Yes. Carmen has the same mutation as Sofía. Nobody knew until Carmen was 28 years old. Those 28 years of high LDL — from birth — were accumulating in Carmen’s heart arteries silently, without symptoms. The heart arteries do not hurt when they narrow — the damage is invisible. When Carmen reached 32, there was already enough accumulated plaque to cause the heart attack. She started treatment at 28, but there was too much damage already done.)

Abuela Dolores was very still. Sofía put her hand in her grandmother’s lap. Neither of them spoke for a moment.

“Sofía tiene 9 años,” Patricia said. “Tenemos una oportunidad que Carmen no tuvo: empezar el tratamiento antes de que el daño ocurra. Si mantenemos el LDL de Sofía por debajo de 130 desde ahora — ella ya está en 148, está bajando — las arterias del cora&zón de Sofía van a llegar a los 30, 40, 50 años en mucho mejor condición que las de su mamá. La rosuvastatina es muy bien tolerada en niños de la edad de Sofía — llevamos más de 20 años usanádola en niños con FH, y la dosis de 5 miligramos es la más baja que existe. Le revisamos el hígado y los músculos en cada visita. Sofía está bien.” (Sofía is 9 years old. We have an opportunity that Carmen did not have: to start treatment before the damage occurs. If we keep Sofía’s LDL below 130 from now — she is already at 148, it is going down — Sofía’s heart arteries are going to reach ages 30, 40, 50 in much better condition than her mother’s. Rosuvastatin is very well tolerated in children Sofía’s age — we have been using it in children with FH for over 20 years, and the 5 milligram dose is the lowest there is. We check her liver and muscles at every visit. Sofía is doing well.)

Abuela Dolores looked at her granddaughter. She straightened Sofía’s ponytail, which had been abandoned mid-braid. “Yo siempre le doy la pastilla,” she said. “Todos los días. No me la salto nunca.” (I always give her the pill. Every day. I never miss it.)

“Lo sabemos — el número de hoy lo confirma.” (We know — today’s number confirms it.)

Sofía looked at the nurse. “¿Mi mamá se va a poner bien?” (Is my mother going to get better?)

“Tu mamá está recibiendo muy buen cuidado. Y lo mejor que tú puedes hacer por tu mamá es que cuando seas grande, el cora&zón de Sofía esté sano. Para eso es la pastilla.” (Your mother is getting very good care. And the best thing you can do for your mother is that when you are grown, Sofía’s heart is healthy. That is what the pill is for.)

Scenario 3: Andrés Torres-Espinoza — 14 years old, Dallas, Texas

Andrés Torres-Espinoza had been the tallest person at his middle school for two consecutive years before his growth spurt accelerated at age 14 and left him the tallest person in the first three rows of his high school’s freshmen photograph. He had grown 8 centimeters in the past twelve months. His shoe size had gone from 9 to 12. His mother Lucía Torres-Morales, who worked as a legal assistant and had negotiated two pay raises in the same calendar year, applied the same research intensity to her son’s medical care.

Andrés had been diagnosed with heterozygous FH at age 12 — not through family history, as his father’s side was not medically available, but through a random cholesterol panel ordered during an urgent care visit for a sports physical. Total cholesterol 378 mg/dL, LDL 298 mg/dL. The pediatrician had referred immediately. The pediatric lipid clinic had confirmed LDLR pathogenic variant. After dietary modification: LDL 276 mg/dL. Atorvastatin 20 mg daily had been started at age 12.5 years. Eighteen months later, LDL was 168 mg/dL.

Lucía arrived at the eighteen-month statin follow-up with a printed list of questions. She waited until the nurse, Carmen Vásquez-Espinoza, had reviewed the chart, then placed the list on the table. “Tengo preguntas sobre el medicamento. Andrés está en pleno crecimiento — usted puede ver que creció ocho centímetros este año. Leí varios artículos sobre las estatinas y encontré estudios que dicen que pueden causar daño muscular y posiblemente afectar el crecimiento de los huesos. Andrés tiene las placas de crecimiento todavía abiertas — lo confirmó la radiografía del año pasado. No quiero darle un medicamento que interfiera con el crecimiento cuando está creciendo más rápido que nunca. ¿No podemos hacer una pausa hasta que termine de crecer y luego retomamos?” (I have questions about the medication. Andrés is in full growth — you can see he grew eight centimeters this year. I read several articles about statins and found studies that say they can cause muscle damage and possibly affect bone growth. Andrés still has open growth plates — confirmed by last year’s X-ray. I do not want to give him a medication that interferes with growth when he is growing faster than ever. Can we not take a pause until he finishes growing and then pick up again?)

Carmen put down her pen. “Señora Torres, gracias por investigar. Son exactamente el tipo de preguntas que tiene que hacer antes de darle un medicamento crónico a un adolescente que está creciendo. Quiero responderle con los datos específicos que tenemos sobre estatinas y crecimiento, y también explicarle qué pasa en el cuerpo de Andrés durante una pausa.” (Mrs. Torres, thank you for researching. Those are exactly the type of questions you should ask before giving a chronic medication to a growing adolescent. I want to answer you with the specific data we have about statins and growth, and also explain what happens in Andrés’s body during a pause.)

Andrés was on the exam table, feet dangling considerably lower than when he had first sat there at age 12.

“El estudio más grande sobre estatinas y crecimiento en niños con FH se publicó en el New England Journal of Medicine en 2004. Enrollaron 214 niños de 8 a 18 años con el mismo diagnóstico de Andrés. La mitad tomó pravastatina — que es similar a la atorvastatina de Andrés — y la otra mitad tomó placebo. Los midieron cada seis meses durante dos años: altura, peso, masa ósea por DEXA, estadio de pubertad. Al final del estudio, no hubo ninguna diferencia en la velocidad de crecimiento entre los dos grupos. Los niños que tomaron la estatina crecieron exactamente igual que los que tomaron el placebo.” (The largest study on statins and growth in children with FH was published in the New England Journal of Medicine in 2004. They enrolled 214 children ages 8 to 18 with the same diagnosis as Andrés. Half took pravastatin — which is similar to Andrés’s atorvastatin — and the other half took placebo. They were measured every six months for two years: height, weight, bone mass by DEXA, puberty staging. At the end of the study, there was no difference in growth rate between the two groups. The children who took the statin grew exactly the same as those who took the placebo.)

Lucía made a note on her paper. “¿Y eso por qué? ¿Por qué no afectan el crecimiento?” (And why is that? Why do statins not affect growth?)

“Las placas de crecimiento — el tejido donde los huesos crecen en largo — funcionan mediante un proceso en el que las células del cartílago se multiplican y se convierten en hueso. Ese proceso está controlado principalmente por la hormona del crecimiento y el factor de crecimiento IGF-1. Las estatinas bloquean una enzima en el hígado llamada HMG-CoA reductasa que produce colesterol. Ese bloqueo no afecta la hormona del crecimiento ni el IGF-1 — son caminos completamente distintos en el cuerpo. Los estudios de imagen en niños que toman estatinas muestran que las placas de crecimiento tienen el mismo aspecto, el mismo grosor, y la misma actividad que en niños que no toman estatinas. El crecimiento de Andrés — esos 8 centímetros — no está siendo tocado por la atorvastatina.” (The growth plates — the tissue where bones grow in length — function through a process in which cartilage cells multiply and become bone. That process is controlled primarily by growth hormone and the IGF-1 growth factor. Statins block an enzyme in the liver called HMG-CoA reductase that produces cholesterol. That block does not affect growth hormone or IGF-1 — they are completely different pathways in the body. Imaging studies in children taking statins show that the growth plates have the same appearance, the same thickness, and the same activity as in children not taking statins. Andrés’s growth — those 8 centimeters — is not being touched by atorvastatin.)

Lucía looked at her note. “¿Y los músculos? Leí que las estatinas pueden causar problemas musculares.” (And the muscles? I read that statins can cause muscle problems.)

“El riesgo muscular de las estatinas existe — no voy a decirle que no. En adultos, especialmente con dosis altas o combinados con ciertos otros medicamentos, puede haber inflamación muscular. En niños con las dosis que usa Andrés — 20 miligramos de atorvastatina — el riesgo es muy bajo. Por eso revisamos el CK — la enzima que se eleva cuando los músculos están dañados — en cada visita. El CK de Andrés ha sido normal en todas las visitas, incluyendo esta. Si Andrés alguna vez sintiera dolor muscular inexplicable o debilidad, debería decírselo a la familia y a nosotros inmediatamente — eso sería una señal de que necesitamos revisar la dosis. Pero basados en dieciocho meses sin ese problema, no hay evidencia de que la atorvastatina le esté causando daño muscular.” (The muscle risk of statins exists — I am not going to tell you it does not. In adults, especially at high doses or combined with certain other medications, there can be muscle inflammation. In children at the doses Andrés uses — 20 milligrams of atorvastatin — the risk is very low. That is why we check CK — the enzyme that rises when muscles are damaged — at every visit. Andrés’s CK has been normal at every visit, including this one. If Andrés ever felt unexplained muscle pain or weakness, he should tell the family and us immediately — that would be a sign that we need to review the dose. But based on eighteen months without that problem, there is no evidence that atorvastatin is causing muscle damage.)

Lucía was writing. “¿Y si esperamos a que termine de crecer? ¿Qué tan malo es eso?” (And if we wait until he finishes growing? How bad is that?)

“Quiero que entienda lo que pasa durante ese tiempo. Andrés tiene 14 años. Si termina de crecer a los 17 o 18, estamos hablando de tres o cuatro años de pausa. Durante esos tres o cuatro años, si no hay atorvastatina, el LDL de Andrés vuelve a 298 en dos a cuatro semanas. A 298, el LDL está depositándose en las arterias del corazón de Andrés todos los meses, todos los años — durante esos tres o cuatro años que pauséramos. El crecimiento de Andrés no para el depósito de colesterol. Las arterias no saben que está en pubertad. Y esos tres o cuatro años se suman a los dos años antes del diagnóstico cuando Andrés también estuvo con LDL alto. El FH sin tratamiento en hombres produce infartos en promedio en los 40 a los 50 años — eso es lo que estamos intentando que no le pase a Andrés. Cada año que reducimos ese LDL es un año menos de placa en las arterias.” (I want you to understand what happens during that time. Andrés is 14 years old. If he finishes growing at 17 or 18, we are talking about a three- or four-year pause. During those three or four years, without atorvastatin, Andrés’s LDL returns to 298 within two to four weeks. At 298, LDL is depositing in Andrés’s heart arteries every month, every year — during those three or four years we would pause. Andrés’s growth does not stop cholesterol deposition. The arteries do not know he is in puberty. And those three or four years add up to the two years before diagnosis when Andrés also had high LDL. Untreated FH in men produces heart attacks on average in the 40s to 50s — that is what we are trying to prevent from happening to Andrés. Every year we reduce that LDL is one year less of plaque in the arteries.)

Andrés had been quiet through the whole exchange. “¿Cuándo me dió el diagnóstico, cuánto tiempo ya tenía yo el LDL alto?” (When I got the diagnosis, how long had I already had high LDL?)

“Desde que naciste. La mutación está en el gen — el LDL empieza a subir desde que el hígado empieza a funcionar. A los 12 años, ya tenías 12 años de LDL alto antes de empezar a tratarlo.” (Since you were born. The mutation is in the gene — the LDL starts rising from when the liver starts functioning. At age 12, you already had 12 years of high LDL before you started treating it.)

Andrés looked at his mother. “Mamá, yo no quiero la pausa.” (Mom, I do not want the pause.)

Lucía looked at her list of questions, then at her son — tall, growing, perfectly healthy in every visible respect. She folded the paper. “¿El estudio ese del NEJM — el de los 214 niños — puedo leerlo yo?” (That NEJM study — the one with 214 children — can I read it myself?)

“Se llama Wiegman et al., 2004, New England Journal of Medicine. Título: 'Efficacy and Safety of Statin Therapy in Children with Familial Hypercholesterolemia.' Le puedo imprimir el resumen.” (It is called Wiegman et al., 2004, New England Journal of Medicine. Title: 'Efficacy and Safety of Statin Therapy in Children with Familial Hypercholesterolemia.' I can print the abstract for you.)

“Sí, por favor.” (Yes, please.)

Carmen printed it. Lucía read the abstract standing, then folded it into the paper with her questions. “Continuamos,” she said. (We continue.)